MX351482B - Vaccine against rsv. - Google Patents

Vaccine against rsv.

Info

Publication number
MX351482B
MX351482B MX2014011340A MX2014011340A MX351482B MX 351482 B MX351482 B MX 351482B MX 2014011340 A MX2014011340 A MX 2014011340A MX 2014011340 A MX2014011340 A MX 2014011340A MX 351482 B MX351482 B MX 351482B
Authority
MX
Mexico
Prior art keywords
vaccine against
rsv
against rsv
serotype
protein
Prior art date
Application number
MX2014011340A
Other languages
Spanish (es)
Other versions
MX2014011340A (en
Inventor
Vellinga Jort
Radosevic Katarina
H H V Custers Jeróme
N Widjojoatmodjo Myra
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Priority claimed from PCT/EP2013/055943 external-priority patent/WO2013139916A1/en
Publication of MX2014011340A publication Critical patent/MX2014011340A/en
Publication of MX351482B publication Critical patent/MX351482B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
MX2014011340A 2012-03-22 2013-03-21 Vaccine against rsv. MX351482B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22
PCT/EP2013/055943 WO2013139916A1 (en) 2012-03-22 2013-03-21 Vaccine against rsv

Publications (2)

Publication Number Publication Date
MX2014011340A MX2014011340A (en) 2015-05-11
MX351482B true MX351482B (en) 2017-10-03

Family

ID=52580709

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014011340A MX351482B (en) 2012-03-22 2013-03-21 Vaccine against rsv.
MX2014011341A MX352908B (en) 2012-03-22 2013-03-21 Vaccine against rsv.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014011341A MX352908B (en) 2012-03-22 2013-03-21 Vaccine against rsv.

Country Status (8)

Country Link
KR (1) KR20190107182A (en)
BR (1) BR112014023195B1 (en)
CL (2) CL2014002499A1 (en)
HK (2) HK1206272A1 (en)
IL (2) IL234760A (en)
MX (2) MX351482B (en)
PH (2) PH12014502013B1 (en)
ZA (2) ZA201406890B (en)

Also Published As

Publication number Publication date
HK1206272A1 (en) 2016-01-08
PH12014502086B1 (en) 2014-11-24
KR20190107182A (en) 2019-09-18
IL234758A (en) 2016-07-31
MX2014011341A (en) 2015-05-11
PH12014502013A1 (en) 2014-11-24
PH12014502013B1 (en) 2014-11-24
HK1206274A1 (en) 2016-01-08
MX2014011340A (en) 2015-05-11
CL2014002499A1 (en) 2015-01-09
IL234760A (en) 2016-07-31
MX352908B (en) 2017-12-13
CL2014002500A1 (en) 2015-01-16
ZA201406892B (en) 2015-12-23
ZA201406890B (en) 2015-12-23
PH12014502086A1 (en) 2014-11-24
BR112014023195B1 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
MY169331A (en) Vaccine against rsv
CY1121600T1 (en) STABILIZED SOLUTIONS RSV F ADHESION POLYPEPTIDES
PH12018500856A1 (en) Respiratory syncytial virus vaccine
CY1117673T1 (en) Recombinant RSV antigens
WO2018089851A3 (en) Influenza vaccine
EP3551193A4 (en) Respiratory virus nucleic acid vaccines
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
EA201890527A1 (en) THERAPEUTIC VACCINES AGAINST HPV18
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
HK1205459A1 (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine (mva)(rsv)
MX2021001053A (en) Influenza virus vaccines and uses thereof.
WO2016086088A3 (en) Wound healing through sirt1 overexpression
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2006115843A3 (en) Nipah virus vaccines
WO2012021730A3 (en) Respiratory syncytial virus (rsv) vaccine
MX2018005462A (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use.
WO2013152274A8 (en) Epitope- scaffold immunogens against respiratory syncytial virus (rsv)
WO2012058493A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
WO2015041924A8 (en) Recombinant respiratory syncytial virus (rsv) and vaccines
PH12014502086B1 (en) Vaccine against rsv
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRvIII SEQUENCE FOR THE TREATMENT OF TUMORS
ZA201500606B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
MA39900A (en) Nucleic acid vaccines
MX2012006516A (en) Vaccine adjuvant composition based on ursolic acid.
TH1101001042B (en) Recombinant vector containing the gene encoding human glucokinase.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: MAHLE INTERNATIONAL GMBH